Latest Europe News

Falcon Metals has raised A$30 million through a placement priced at A$0.60 per share, bolstering its capacity to expand diamond drilling at Blue Moon and initiate maiden reverse-circulation drilling at Errabiddy.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Austco Healthcare has delivered record FY26 financial results, driven by strong organic growth, acquisitions, and a growing software maintenance base, positioning the company for sustained earnings momentum.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

RocketBoots reported a 9.7% revenue rise to A$724,815 but deepened its net loss to A$6.6 million, driven by heavy investment ahead of a major contract rollout and international growth.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

Credit Clear Limited posted a 28% rise in FY26 revenue to $60 million, boosted by UK acquisitions and organic growth, while defending legal action by the ACCC.